초록 ▼

This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to

This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis. This invention also provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis.

대표청구항 ▼

1. A method of treating a subject afflicted with rheumatoid arthritis comprising administering to the subject daily, 0.2-2.0 mg of laquinimod or pharmaceutically acceptable salt thereof and 1-3 mg of methotrexate, wherein the amounts when taken together are more effective to treat the subject than w

1. A method of treating a subject afflicted with rheumatoid arthritis comprising administering to the subject daily, 0.2-2.0 mg of laquinimod or pharmaceutically acceptable salt thereof and 1-3 mg of methotrexate, wherein the amounts when taken together are more effective to treat the subject than when each agent is administered alone. 2. The method of claim 1, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof and the amount of methotrexate when taken together is effective to reduce a clinical symptom of rheumatoid arthritis in the subject. 3. The method of claim 1, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium. 4. The method of claim 1, wherein the administration of laquinimod or pharmaceutically acceptable salt thereof is effected orally. 5. The method of claim 1, wherein the administration of methotrexate is effected orally. 6. The method of claim 1, further comprising administration of nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, hydroxychloroquine, sulfasalazine, corticosteroids, cytotoxic drugs, immunosuppressive drugs and/or antibodies. 7. The method of claim 1, wherein the administration of laquinimod or pharmaceutically acceptable salt thereof and methotrexate reduces the severity of a symptom associated with rheumatoid arthritis. 8. The method of claim 1, wherein the administration of laquinimod or pharmaceutically acceptable salt thereof and methotrexate reduces the number of joints affected by a symptom associated with rheumatoid arthritis. 9. The method of claim 1, wherein the subject is a mammal. 10. The method of claim 9, wherein the mammal is human.